May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam. Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on no

May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA).[1] Geographic atrophy (GA) is an eye disease that can lead to irreversible vision loss.[2] It affects more than five million people worldwide, of which more than 40% are considered blind, ,[3],[4] severely impacting their independence, mental health and quality of

May 07, 2025 -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new results with LX-101 in Thyroid Eye Disease (TED) have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, on May 7th in Salt Lake City, Utah. These new data highlight LX-101’s ability to effectively target multiple key processes in the underlying i

Provides ReciBioPharm’s customers with access to NewBiologix’s Xcell-Eng-HEK293 cell lines for advanced therapies Complements and further expands ReciBioPharm’s AAV offering Achieves industry-leading results across multiple AAV programs May 08, 2025 -- NewBiologix, a technology innovation company enabling efficient, cost-effective, and scalable production of viral vectors for cell and gene therapy (C>), today announced it has granted a non-exclusive technology license to ReciBioPharm – Reci

May 07, 2025 -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present new preclinical results on its GalOmic small‑interfering RNA (siRNA) candidate ETX‑312 for the treatment of metabolic dysfunction‑associated steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Congress, 7th-10th May 2025. In the leading Gubra‑Amylin NASH diet‑induced obese (GAN‑DIO) mouse

Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 2025 May 07, 2025 -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune dise

Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control arm Elraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data analysis Clinical trial meets primary endpoint for overall survival and confirms significant 1-year survival rate Elraglusib/GnP combination arm demonstrated a favorable risk-benefit profile Topline dataset to be presented in an oral presentation

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients. All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores. TSPO-PET imaging showed significant reductions in microglial activation at six months (p<0.05). May 06, 2025 -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with it

Completed seed financing round of $7 million from an institutional investor and ImmuneWalk’s management team Includes oral presentation of positive safety, pharmacokinetic, and pharmacodynamic data from immunology and inflammation (I&I) candidate IW-601’s Phase 1 single ascending dose study May 07, 2025 -- ImmuneWalk Therapeutics, a clinical stage company focused on modulating immune and inflammatory disease through monocyte inhibition, today announced the completion of a $7 million seed fina

May 6, 2025 – Italfarmaco S.p.A. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to givinostat for the treatment of patients with polycythemia vera (PV), a rare haematologic cancer, for which treatment options are limited. “The FDA decision to grant givinostat Fast Track designation underscores the urgent need for innovative treatments for PV and highlights the potential of givinostat to make a meaningful difference,” said Paolo Bettica, MD, P